 | 1993 - 192 lapas
...statement of the general pharmacological action(s) of the mixture or of its principal intended action(s) in terms that are meaningful to the layman. Such statements...the package rests as it is designed to be displayed. §201.62 Declaration of net quantity of contents. (a) The label of an over-the-counter drug in package... | |
 | 1981 - 254 lapas
...proprietary name or designation and shall employ terms descriptive of general pharmacological category(ies) or principal intended action(s); for example, "antacid,"...the package rests as it is designed to be displayed. §201.62 Declaration of net quantity of contents. (a) The label of an over-the-counter drug in package... | |
 | 1971 - 748 lapas
...indications for use shall be included in the directions for use of the drug, as required by section 502(f)(l) of the act and by the regulations in this part. (c)...designed to be displayed. [33 FR 9482, June 28, 1968] § 1.102b Drugs and devices in package form; labeling re name and place of business of manufacturer,... | |
 | 1988 - 590 lapas
...intended action(s). The indications for use shall be included in the directions for use of the device, as required by section 502(f)(1) of the act and by...the package rests as it is designed to be displayed. §801.62 §801.62 Declaration of net quantity of contents. (a) The label of an over-the-counter device... | |
 | 1974 - 258 lapas
...indications for use shall be Included in the directions for use of the drug, as required by section 502(f)(l) of the act and by the regulations in this part. (c)...package rests as it is designed to be displayed. [ 33 PR 9482. June 28, 1968 1 § 1.1021» Drugs and device« in package form ; labeling re name and place... | |
 | 1972 - 488 lapas
...indications for use shall be included in the directions for use of the drug, as required by section 502(f)(l) of the act and by the regulations in this part. (c)...package rests as it is designed to be displayed. [33 PR 9482. June 28, 1968] § 1. 1021. Drugs and devices in package form; labeling re name and place of... | |
 | 1997 - 200 lapas
...indications for ose shall be included in the directions for use of the drug, as required by section 502(0(1) of the act and by the regula-tions in this part. (c)...the package rests as it is designed to be displayed. {201.62 Declaration of net quantity of content*. (a) The label of an over-the-counter drug in package... | |
 | 2000 - 264 lapas
...indications for use shall be included in the directions for use of the drug, as required by section 502(f)(l) of the act and by the regulations in this part. (c)...matter on such panel, and shall be in lines generally patai\e\ to the base on which the package rests as it is designed to be displayed. $201.62 Declaration... | |
 | 2002 - 216 lapas
...vignette representing the intended cosmetic use. (c) The statement of identity shall be presented in bold type on the principal display panel, shall be in a...the package rests as it is designed to be displayed. § 701.12 Name and place of business of manufacturer, packer, or distributor. (a) The label of a cosmetic... | |
 | 1982 - 554 lapas
...section 401 of the act. (d) This statement of identity shall be presented in bold type on the prinnpal display panel, shall be In a size reasonably related...the package rests as it Is designed to be displayed. te> Under the provisions of section 4O3(c) of the Federal Food, Drug, and Cosmetic Act, a food shall... | |
| |
... etc. The indications for use shall be included in the directions for use of the drug, as required by section 502(f)(1) of the act and by the regulations in this part. (c) The statement of identity shall be presented in bold face type on the principal... 
